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Effects of 25-hydroxycholecalciferol on bone lesions of children
with terminal renal failure. Quantitative histology was performed
on serial iliac crest biopsies obtained from 14 children with termi-
nal renal failure. A long-term study on the comparative effects of
vitamin D2 and 25-hydroxycholecalciferol 125-(OH)D,], in five
patients with severe lesions of osteomalacia and/or osteitis fibrosa,
demonstrated the efficiency of 25 to 200 sg/day of 25-(OH)D3 and
the lack of therapeutic action of 345 to 685 sg/day of vitamin D2.
In nine subjects with normal roentgenograms or minimal skeletal
alterations, the first biopsy taken at the beginning of intermittent
hemodialysis showed evidence of defective mineralization and/or
lesions of resorption. Four of these children were treated with 25-
(OH)D3 (25 to 50sg/day) and calcium supplementation orally (0.5
to 1.5 g/day); five children received calcium orally (0.5 to 0.75
g/day) alone. Aggravation of bone lesions during intermittent
hemodialysis was observed in patients treated with calcium supple-
ments alone. In subjects who were given 25-(OH)D3, miner-
alization improved and marrow fibrosis disappeared. However, as
the two groups of patients were different in composition and in the
manner in which they were treated, it is difficult to state whether
the beneficial effects observed were solely attributable to 25-
(OH)D3 administration. 25-(OH)D3 therapy induced severe in-
toxication in two patients. A rise in plasma calcium concentration
to 11.0 to 11.5 mg/l00 ml was observed in two other patients. It is
concluded that: a) pharmacologic doses of 25-(OH)D3 are highly
effective in healing bone lesions of children with terminal renal
failure; b) such treatment requires strict clinical surveillance as 25-
(OH) D3 intoxication may occur even in anephric patients.
Effets du 25-hydroxycholecalciferol sur les lesions osseuses dans
l'insuffisance renale terminale de I'enfant. Le tissu osseux de qua-
torze enfants en insuffisance rénale terminale a été étudié par des
techniques d'histologie quantitative sur des biopsies itératives
de Ia crete iliaque. Chez cinq malades ayant des lesions sévCres
d'ostéomalacie et/ou d'ostéite fibreuse Ia comparaison des effets
thérapeutiques a long terme de Ia vitamine D2 (345 a 685 mg/jour)
et du 25-(OH)D3 (25 a 200sg/jour) a mis en evidence Ia grande
efficacité du 25-(OH)D3 et Ic manque d'action de La vitamine D.
Chez neufenfants devant être traités par hémodialyse chronique et
dont les radiographies du squelette Ctaient normales ou a peine
altérées, les biopsies ont montré un défaut de minéralisation et/ou
des lesions de resorption. Parmi ces sujets quatre malades ont
recu un traitement associant 25-(OH)D, (25 a 50 tg/jour) et une
supplementation orale de calcium (o,5 a 1,5 g/jour), les cinq
autres seulement du calcium (o,5 a o,75 g/jour). Chez les malades
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recevant seulement une supplementation orate de calcium les lé-
sions osseuses se soot aggravées sous hémodialyse chronique; par
contre chez tes malades recevant du 25-(OH)D3 Ia minéralisation
s'est améliorCe et Ia fibrose médullaire a disparu. Cependan, Ia
composition des deux groupes de malades et leur traitement
n'ayant pas été identiques, il est diffcile d'affirmer que les améliora-
tions observées ne sont dues qu'au 25-(OH)D3. Chez deux mal-
ades, Ic 25-(OH)D3 a entrainé une intoxication sévCre. Chez deux
autres Ia calcémie s'est élevée a 11,0 -11,5 mg/lOO ml. En con-
clusion, ces résultats montrent: a) l'activitC thérapeutique du 25-
(OH)D3 sur les lesions osseuses d'enfants en insuffisance rénale
terminate; b) Ia possibilité d'intoxication par Ic 25-(OH)D3 même
de sujets anéphriques d'ofl Ia nCcessité d'une surveillance clinique
et biologique constante de tout malade traité par ce dérivé de Ia
vitamine D.
Osteodystrophy is a disabling complication of
renal failure. In 1966 we reported that among 149
cases of renal failure analyzed, 41 patients (27.5%)
had severe osseous abnormalities [I]. These results,
showing that the incidence of renal osteodystrophy in
children and adolescents is higher than that reported
in adults, are in agreement with more recent studies
by Fine et al [2]. Since 1966, we have observed a
marked decrease in the percentage of uremic patients
developing skeletal alterations (unpublished data).
This was achieved as a result of a systematic therapy
designed to prevent hyperparathyroidism. This treat-
ment included administration of vitamin D2 or D3
(4,000 to 12,000 lU/day or 100 to 300 tg/day) and
calcium supplements orally (0.5 to 1.5 g/day) to all
patients with creatinine clearances less than 60
ml/min/1.73 m2, and the prescription of aluminum
gels when plasma phosphorus concentrations were
higher than 6.0 mg/100 ml. Vitamin D, calcium sup-
plements, and aluminum gels were stopped or doses
modified for each patient according to roentgenogra-
phic and biochemical changes observed during fol-
low-up.
However, this therapeutic approach did not eradi-
cate severe bone lesions in all of our patients with
renal insufficiency. Therapeutic failures were attri-
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buted to late diagnosis, inadequate patient com-
pliance in taking prescribed medication, especially
phosphorus-chelating drugs, and possibly other fac-
tors undetectable by our current means of in-
vestigation. To this small number of patients with
overt bone alterations, one has to add a new group of
patients prone to skeletal lesions: children and ado-
lescents undergoing long-term hemodialysis. In fact,
we have observed in some patients receiving mainte-
nance hemodialysis the appearance, persistance and
increase of bone lesions. The use, since 1972, of soft-
ened water and calcium-rich dialysate (3 to 3.5
mEq/liter) has not completely abolished the occur-
rence of skeletal complications, a finding in agree-
ment with the results of several investigators [3—7].
These observations led us to attempt a therapeutic
trial with 25-hydroxycholecalciferol [25-(OH)D3] for
these patients. Our reasons for choosing this metabo-
lite, despite the fact that it is generally considered a
simple circulating form of vitamin D, were the fol-
lowing: I) Results from our laboratory and from
other investigators have clearly shown that pharma-
cologic doses of 25-(OH)D3 are active even in the
absence of kidney tissue [8—11]. 2) The more potent
kidney-made hormonal form of vitamin D3, 1,25-
dihydroxycholecalciferol, or its synthetic analog, l,-
hydroxyvitamin D3, was not available for long-term
therapy.
The present paper reports: a) the comparative ef-
fects of 25-(OH)D3 and vitamin D on severe lesions
of renal osteodystrophy, b) the evolution of bone
lesions during maintenance hemodialysis in patients
treated with 25-(OH)D3 plus calcium orally and in
patients treated orally with calcium alone, and c) the
tolerance of uremic children to long-term administra-
tion of pharmacologic doses of this vitamin D me-
tabolite.
Methods
Fourteen patients aged 4 yr, 2 months to 16 yr, 8
months were the subjects of this investigation. They
had severe renal failure with endogenous creatinine
clearances less that 10 ml/min/l.73 m2. Table 1 sum-
marizes their main clinical data. Two groups of sub-
jects were studied.
Children of group I were characterized by severe
lesions of osteodystrophy (patients ito 5). They were
the only ones with such lesions among the patients
seen in our department between November, 1969, and
November, 1970. All of them had a congenital dis-
ease. At the time the first bone biopsy was performed,
these patients had had symptoms of severe glomeru-
lar functional impairment for more than four years.
For these subjects, the therapeutic effects of 25-
(OH)D3 and of vitamin D2 (Sterogyl, Laboratoire
Roussel, Paris, France) were compared.
Children of group II (patients 6 to 14) had essen-
tially normal radiograms. Three subjects (patients 7,
10 and 12) had congenital diseases; five subjects
(patients 6, 8, 9, 11 and 13) had acquired diseases
which had progressed to terminal renal failure within
the two years preceding the first biopsy. One patient
was anephric due to the removal of a solitary kidney
after a traffic accident. These patients had recently
been started on a program of intermittent hemo-
dialysis (patients 6 and 8) or such a program was
begun during the week(s) following their first bone
biopsy. These nine patients were randomly distrib-
uted in two subgroups: subjects of group Il-A
(patients 6, 7, 8 and 9) received 25-(OH)D3 and cal-
cium supplements orally; subjects of group If-B
(patients 10, 11, 12, 13 and 14) received calcium,
orally, alone (Calcium "forte", Laboratoires Sandoz,
Rueil-Malmaison, France). The doses of elementary
calcium prescribed varied from 0.5 to 1 .5 g/day. All
children were prescribed aluminum hydroxide gel
(Lithiagel, Laboratoire Brunet, Boulogne sur Seine,
France), i.e., 5 to 90 mI/day; the content of this
preparation is expressed by the manufacturer as per-
cent of aluminum (Al203), i.e., 5.85 g/100 ml.
This second investigation was designed to analyze
the preventive action of 25-(OH)D3 on bone lesions
during intermittent hemodialysis (IHD).
Intermittent hemodialysis. Hemodialysis was per-
formed with a disposable multilayer RP5 dialyzer.
Patients were dialyzed for eight to ten hours two
times weekly. For two patients of group I who re-
quired IHD (patients 4 and 5), the dialysate was
prepared with softened water and a calcium concen-
tration of 6.0 mg/l00 ml (3 mEq/Iiter). Among the
subjects of group II, only one patient treated with 25-
(OH)D3 plus calcium supplements (patient 6) and
one treated with calcium supplements alone (patient
11), were dialyzed with this type of fluid. For the
others softened water with 7.0 mg/100 ml (3.5
mEq/liter) of calcium was utilized. All patients were
prescribed a diet with limited sodium and protein
intake; they received hydrosoluble vitamins, iron,
and exchange resins.
Radiological evaluation, The severity of bone le-
sions was evaluated on standard radiograms by three
investigators. Roentgenograms were obtained a few
days to two months before the first bone biopsy, then
every six months and/or immediately prior to or after
the second biopsy.
The skeletal lesions were classified as metaphyseal
abnormalities and lesions of osteitis fibrosa. Their
degree of severity was designated from + to +++.
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When the radiological features were considered as
almost normal, (0), by two investigators and as + by
the third, the sign (+) was given. The metaphyseal
lesions were assessed at the ends of long bones: + and
++ were used to indicate abnormalities of the
growth plate's calcification lines, such as small irregu-
larities or blurred and fragmented lines. When frayed
metaphyses with varus or valgus deformities of the
lower extremities or slipped epiphyses were present,
the lesions were designated as + + +. The term "rick-
ets" (R) was used only for those metaphyseal lesions
showing all the characteristics usually associated with
nutritional rickets, i.e., widened metaphyseal-epi-
physeal distances, cupped and enlarged metaphyses.
The lesions of osteitis fibrosa were looked for on
radiograms of the phalanges; the cortical bone of the
tibia, femur, and humerus; the vault of the skull; and
the lamina dura around the teeth sockets. They were
classified as follows: (+) or + = granular rarefaction
of the vault of the skull and/or few subperiosteal
erosions of phalanges; + + = evident and numerous
subperiosteal erosions of phalanges and loss of la-
mina dura; +++ = partial dissolution of terminal
phalanges, multiple cystic rarefactions, subperiosteal
cortical resorption of long bones. Bone density was
evaluated by measuring the cortical and the diaphy-
seal thickness of the left tibia at equal distances from
the two growing plates. The values were expressed as
the cortico-diaphyseal ratio,
CDR = diaphyseal thickness — cortical thickness
diaphyseal thickness
According to Bernard eta! [121, normal values for the
age group studied range from 0.40 to 0.55.
Bone histology. All patients had two biopsies. Bone
specimens were obtained from the anterior iliac crest
by the technique of Bordier et al [13]. For the major-
ity of the subjects, the biopsies were performed under
general anesthesia during a required surgical pro-
cedure, i.e., arteriovenous shunt or fistula for hemo-
dialysis, nephrectomy or transplantation. The inter-
val between the first and the second biopsy varied
from two months (patient 4) to sixteen months
(patient 6); however, for most children this interval
was of five to eight months' duration. The bone sam-
ples, fixed in ethyl alcohol, were embedded in meth-
ylmetacrylate without previous decalcification. Slices
obtained with a diamond wheel sectioning machine
(Gillings—Hamco thin sectioning machine, Roches-
ter, N.Y., U.S.A.). were hand-ground to l5tm thick-
ness and stained with basic fuchsine or eosine-azur.
Histological measurements were performed with
Zeiss integrating eyepieces at magnification X 200 in
trabecular bone. For each specimen the mean of
2,000 counts was used for "volume" data and the
mean of 1,000 counts for "surface" data.
For quantitative evaluation of bone structure and
formation the following parameters were chosen [14,
15]:
bone volume: fraction (%) of spongiosa volume repre-
sented by bone matrix;
calcified volume: fraction (%) of spongiosa volume
represented by calcified tissue;
osteoid volume: fraction (%) of spongiosa volume rep-
resented by osteoid;
osteoid "surface": fraction (%) of trabecular surface
lined by osteoid;
osteoblast "surface": fraction (%) of trabecular sur-
face lined by osteoblasts;
relative osteoblastic activity: fraction (%) of osteoid
surface covered by osteoblasts;
mean osteoid seam thickness (am): osteoid volume
divided by osteoid surface.
In normal bone, osteoblastic activity and osteoid
volume are in close relation, thus reflecting the syn-
chronization between the rate of matrix formation
and the rate of mineralization. In pathological condi-
tions this synchronization may be disturbed. In os-
teomalacia there is too much osteoid compared to
the number of osteoblasts; this indicates a delayed
mineralization (increased osteoid volume, increased
osteoid seam thickness, and decreased relative Os-
teoblastic activity). In contrast, in hyperparathy-
roidism the increased amount of osteoid goes with
an increase in the number of bone-forming os-
teoblasts; this indicates undisturbed mineralization
and increased bone formation (increased osteoid
volume, normal osteoid seam thickness, and in-
creased relative osteoblastic activity) [16].
For quantitative evaluation of bone resorption and
osteitis fibrosa, the following parameters were chosen
[17]: osteoclast surface = fraction (%) of trabecular
surface covered by osteoclasts, marrow fibrosis vol-
ume = fraction (%) of spongiosa volume occupied by
fibrous tissue.
Plasma chemistry. Plasma calcium and phosphorus
concentrations and plasma alkaline phosphatases
were checked regularly. In the patients submitted to
IHD, blood samples were obtained immediately be-
fore dialysis. The following techniques were used:
plasma calcium, atomic spectrophotometry (Perkin
Elmer); plasma phosphorus, Fiske and Subbarow
technique adapted to an autoanalyzer (Technicon,
Daumont, France); plasma alkaline phosphatases,
King and Armstrong method or Bodansky method.
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Table 2. Quantitative bone histology of normal French and American children
25-hydroxycholecalc(ferol. The synthetic 25-(OH)D3
used in this study was a gift from the Laboratoires
Roussel, Paris, France. It was given to the patients
once a day each morning, orally, as propylene glycol
solution.
Normal controls. Due to the fact that specimens
from normal children were not available, we exam-
ined samples that were kindly provided by Dr. J.
Jowsey. Hence, our normal controls concern children
from Minnesota, U.S.A, whose death was caused by
accident. However, as this could not be considered an
ideal control group for patients from France, we
compared our results to those obtained by Dr. P.
Bordier in nine French children aged 5 to 14 yr. The
results of both groups are given in Table 2. Except for
slight but not significant differences in osteoclast sur-
face, all other parameters are comparable in the two
groups.
Results
Group I. Patients with severe osteodystrophy (Tables 1 and 3,
Fig. Iaandb, Fig. 2aand b, Fig. 3)
Quantitative histologic examinations performed on
the first biopsy specimens obtained from the five chil-
dren with severe osseous abnormalities showed a
marked increase in osteoid and osteoblast surfaces,
and the presence of marrow fibrosis with increased
osteoclast surface.
On the biopsy specimens of the two children
(patients 1 and 2) with predominantly metaphyseal
lesions on roentgenograms, the mean osteoid seam
thickness was greatly increased, and the relative os-
teoblastic activity was normal in patient 1 and low in
patient 2. This indicates delayed mineralization. Os-
teoid was also found deeply embedded in trabeculae;
it contained calcified granules in some areas. The
limit between calcified tissue and osteoid seam was
irregular; the matrix was mainly formed by regularly
oriented collagen fibers. Woven bone was scarce. Os-
teocytic lacunae, often enlarged, contained a large
pale nucleus. The most peculiar osteocytic aspect was
the presence of cells deeply buried in large osteoid
seams, and surrounded by mineral deposits. Marrow
fibrosis was limited and localized under the endos-
teum and parallel to the trabecular surface.
On the biopsy specimens of the patients with pre-
dominantly resorptive lesions on radiograms
(patients 3, 4, and 5), the mean osteoid seam thick-
ness was slightly increased; the relative osteoblastic
activity was very high. This indicates that the miner-
alization was near normal while the formation of
bone was accelerated. In these cases woven calcified
bone and woven osteoid were abundant. The tiny
trabeculae of woven bone were surrounded by a thick
layer of osteoblasts. Osteocytic lacunae were en-
larged, often confluent, and showed a strong me-
tachromatic reaction. Marrow fibrosis was diffuse.
a. Therapeutic effects of vitamin D2. In patients
previously treated with vitamin D (patients 2, 3, and
4), no correlation could be found between the histol-
ogy and vitamin D therapy. In spite of their long-
standing treatment with therapeutic doses of vitamin
D2, i.e., 345 to 685kg/day (13,000 to 27,400 lU/day),
the histological aspect of the bones of patients 3 and 4
were similar to that of patient 5 who had never been
given any vitamin D. For this latter subject a second
bone biopsy specimen was obtained five months after
the initiation of vitamin D2 therapy at daily doses
varying from 300 to 380tg: no clear-cut effect of
vitamin D was observed on bone histology except for
a decrease in marrow fibrosis and an increase in
osteoclast surface (Table 3, patient 5). Her plasma
calcium concentration remained low and was norma-
lized only when she was started on IHD one month
after the beginning of vitamin D therapy.
b. Therapeutic effects of 25-(OH)D3. The bone le-
sions were improved in the four patients treated with
25-(OH)D3 (patients 1 through 4). The main effects
were an improvement of mineralization, a reduction
of osteitis fibrosa and of osteoblasts; osteoclast sur-
face decreased in all but patient 4. The beneficial
effect of 25-(OH)D3 on mineralization was more im-
pressive on the biopsy specimens of the two patients
who had prevailing metaphyseal lesions on roent-
genograms (patients 1 and 2). Their osteoid volumes
as well as their mean osteoid seam thickness were
greatly reduced by treatment (Fig. 1, a and b). The
Bone
volume
Calcified
volume
Osteoid
volume
Osteoid
surface
Osteoblast
surface
Osteoclast
surface
French, N = 9 24.2 + 1.6 20.8 + 2 3.4 + 1.5 27.9 + 9.1 12.3 + 3.7 0.81 0.37
(mean + 1 so)
American, N = 13 22.0 + 1.87 21.1 + 1.73 4.2a 2.01 22.0 + 7.60 8.3 4.44 1.8 + 0.72
(mean I SD)
a Dr. P. Bordier expresses osteoid volume as the percentage of bone volume represented by osteoid tissue. To allow comparison our values
were transformed to represent the same percentage.
Ta
bl
e 
3.
 E
ffe
ct
s 
o
f v
ita
m
in
 D
 o
r 
25
-(O
H)
 D3
 o
n
 fi
ve
 p
at
ie
nt
s w
ith
 se
v
er
e 
le
sio
ns
 o
f o
st
eo
dy
str
op
hy
 
Th
er
ap
y 
B
on
e h
ist
ol
og
y 
R
em
ar
ks
 
D
ai
l 
do
se
 
O
ste
ob
l S
 
_
_
_
_
_
_
_
_
_
_
 
D
ur
at
io
n 
B
on
e 
Ca
lc
ifi
ed
 
O
ste
ojd
 
O
ste
oi
d 
th
ic
kn
es
s 
O
ste
ob
la
st 
O
ste
ol
d S
 
M
ar
ro
w
 
O
ste
oc
la
st 
Pa
tie
nt
 N
o.
 
g 
zg
/k
g 
m
o
n
th
s 
v
o
lu
m
e 
v
o
lu
m
e 
v
o
lu
m
e 
su
rfa
ce
 
(J.
m)
 
su
rfa
ce
 
fib
ro
sis
 
su
rfa
ce
 
I 
N
o 
v
ita
m
in
 D
 th
er
ap
y 
30
.7
 
20
.2
 
10
.5
 
77
.6
 
25
.6
 
27
.0
 
34
.8
 
9.
3 
10
,2
 
A
fte
r 2
5-
(O
H)
D3
 
20
0 
6.
7 
12
 
18
.4
 
17
.2
 
1.
2 
37
.9
 
10
.3
 
8.
8 
23
.2
 
0 
6.
9 
2 
A
fte
r v
ita
m
in
 D2
 
68
5 
41
.5
 
1 
44
.3
 
25
.0
 
19
.5
 
84
.6
 
46
 
16
.5
 
19
.5
 
3.
8 
8.
6 
A
fte
r 2
5-
(O
H)
D3
 
80
 
4.
8 
10
0 
6 
l3
 
12
0 
7.
3 
I 
I 
42
.5
 
34
.0
 
8.
3 
65
 
21
.9
 
2.
7 
4.
2 
0 
5.
6 
H
yp
er
ca
lc
em
ia
 
(15
.8 
m
g/
I0
0 
m
l) 
3 
A
fte
r v
ita
m
in
 D2
 
63
5 
27
.6
 
6 
10
 
34
5 
15
 
4 
I 
27
.5
 
23
.0
 
4.
6 
59
.5
 
17
.2
 
48
.5
 
81
.5
 
36
.8
 
15
.6
 
A
fte
r 2
5-
(O
H)
D3
 
40
 
1.
7 
3 
L 
25
 
1 
6 
22
.1
 
19
.2
 
2.
9 
69
.4
 
13
.2
 
24
.4
 
35
.2
 
3.
2 
6.
0 
4 
A
fte
r v
ita
m
in
 D
2 
(I)
 
43
5 
19
.8
 
24
 
30
.9
 
23
.7
 
7.
2 
75
.7
 
13
 
53
.1
 
70
.1
 
31
.6
 
8.
3 
A
fte
r 2
5-
(O
H)
D3
 
10
0 
4.
5 
2 
16
.4
 
14
.9
 
1.
5 
34
 
8.
3 
3.
0 
8.
7 
2.
8 
10
.0
 
H
yp
er
ca
lc
em
ia
 
(16
.8 
m
g/
lO
O
m
l) 
5 
N
o 
v
ita
m
in
 D
 th
er
ap
y (
2) 
26
.4
 
16
.8
 
9.
6 
67
.7
 
18
.2
 
49
.2
 
72
.7
 
56
.0
 
7.
5 
A
fte
r v
ita
m
in
 D2
 
38
0 
15
.2
 
2 
'1
 
30
0 
12
 
3 
1 
16
.3
 
8.
7 
7.
6 
73
.4
 
18
.9
 
52
.0
 
70
.8
 
38
.9
 
13
.6
 
N
or
m
al
 co
n
tr
ol
sn
 =
 
13
 
22
.0
 
21
.1
 
0.
9 
22
.0
 
9.
3 
8.
3 
36
.9
 
0 
1.
8 
(m
ea
n 
I 
SD
) 
±
1.
87
 
±
1.
73
 
±
0.
42
 
±
7.
60
 
±
3.
74
 
±
4.
44
 
±
14
.3
3 
±
0.
72
 
O
ste
ob
i =
 
o
st
eo
bl
as
t; S
 =
 s
u
rfa
ce
. (I
) h
em
od
ia
ly
ze
d f
or
 tw
o 
m
o
n
th
s; 
(2)
 he
m
od
ia
ly
ze
d 
du
rin
g 
th
e l
as
t f
ou
r 
m
o
n
th
s o
f s
tu
dy
. 
25-Hydroxycholecalciferol.' Effects on osteodystrophy 401
Fig. I. Histologic aspect of bone of patient 2: (a) before and (b) after
25-(OH)D3 a, Osteoid seams (grey) are thick; multinucleated os-
teoclasts (short arrow) erode the calcified tissue (white) in the
middle of trabecula; osteoblasts are flat (long arrow); the marrow
relative osteoblastic activity was also reduced. In
these children, the main action of 25-(OH)D3 was
related to bone mineralization which became normal
in patient 1 and greatly improved in patient 2. The
effect of 25-(OH)D3 on marrow fibrosis and os-
teoclast surface was also marked. It was particularly
notable in the two children (patients 3 and 4) with
severe lesions of osteitis fibrosa on their radiographs.
Their diffuse marrow fibrosis nearly disappeared.
Woven bone was replaced by a tissue formed of par-
allel oriented bundles of collagen. Osteoblast surface
was reduced and osteocytic osteolysis was scarce
(Fig. 2, a and b). In these children the main action of
25-(OH)D3 was related to bone formation, which
became normal in patient 3 and below normal in
patient 4.
For three patients (1, 2 and 4), after three months
of 25-(OH)D3 therapy, the radiologic examination
showed improvement or healing of the metaphyseal
lesions and of the lesions of resorption. For the
fourth subject (patient 3) who had received smaller
doses of 25-(OH)D3, i.e., 4Otg/day for three months,
b
fibrosis is scarce. b, In comparison to the aspect shown in a, the
osteoid seam thickness has decreased, osteoclasts are less numer-
ous, and the marrow fibrosis has disappeared. (Methylmetacrylate,
basic fuchsine, X300.)
then 25zg/day for the subsequent three months, no
changes were detectable on roetgenograms although
histological improvement was evident. Normaliza-
tion of plasma calcium concentrations in the two
hypocalcemic children (patients 1 and 2) was ob-
tained at four and ten weeks, respectively. Plasma
phosphorus concentrations were variable. At the end
of 25-(OH)D3 therapy, plasma alkaline phosphatase
concentrations had returned to normal values in
patient 4, had decreased in patients I and 2, and had
remained unchanged in patient 3.
c. Tolerance to pharmacologic doses of25-(OH)D3.
Doses of 25-(OH)D3 equal to lOOtg/day or higher
were given to three children. These doses were well
tolerated by one patient (Table 3, patient 1), not only
during the one year of this investigation but also
during the following year, up to the time of trans-
plantation when 25-(OH)D3 therapy was stopped.
However, for the two others, 25-(OH)D3 had overt
toxic effects. Both these patients developed severe
hypercalcemia. 25-(OH)D3 intoxication occurred af-
ter three months' therapy in patient 2 who was pre-
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a b
Fig. 2. Histologic aspect of bone of patient 4.' (a) before and (b) after
25-(OH)D3. a, The thin calcified trabeculae are surrounded by
osteoid seams covered by a layer of round-shaped, active os-
teoblasts (long arrow); osteoclasts (short arrow) are eroding calci-
fied tissue; marrow spaces are filled with fibrous tissue (star). b, In
viously hypocalcemic, and after six weeks in patient 4
who was normocalcemjc when 25-(OH)D3 was
started. In the first case (Fig. 3), 25-(OH)D3 was
stopped, the patient was given a low calcium diet (100
mg of calcium a day), and repeated intramuscular
injections of porcine extractive calcitonin (Calcitar,
Laboratoires Armour—Montagu, Paris, France), i.e.,
3 X 60 MRC U/day. Ten days later, his plasma
calcium concentration became normal. For this child
the only clinical manifestation of hypercalcemia had
been tachycardia. For the second patient the in-
toxication was much more severe. Clinical manifesta-
tions included severe hypertension, tachycardia,
headache, mental aberration and convulsions. She
was hemodialyzed with a fluid devoid of calcium, was
given a low calcium diet and 80 MRC U/day of
calcitonin. These treatments decreased her plasma
calcium concentrations to 12.0 to 13.0 mg/lOO ml. As
no further improvement could be obtained, subtotal
parathyroidectomy was performed. At surgery three
comparison to the aspect shown in a, the calcified trabecula is
large, osteoid tissue has disappeared; the active osteoblasts and the
marrow fibrosis have greatly decreased. (Methylmetacrylate, basic
fuchsine, X300.)
hyperplastic parathyroid glands were found and re-
moved.
Group II: Patients with essentially normal radiograi'ns,
started on a program of IHD (Tables 1 and 4, Fig. 4 and 5)
Most patients included in this second group had an
acquired kidney disease (Table 1). The duration of
severe renal failure before IHD was less than 14
months for three children (patients 6, 8 and 9) treated
with 25-(OH)D3 plus calcium (group 11-A), and four
subjects of five (patients 10, 11, 12 and 14) treated
with calcium supplementation (group Il-B). All ex-
cept two children were hypocalcemic. The two ex-
ceptions were patient 6 who had been on IHD for
three months and patient 14 who had been treated
with peritoneal dialysis after the removal of a solitary
kidney. Eight of nine were hyperphosphatemic when
the first biopsy specimen was obtained. The histo-
logic and morphometric studies demonstrated that
not a single child of either subgroup had a normal
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bone structure. The patient who was anephric
(patient 14) and treated by peritoneal dialysis for one
month had a marked diminution of bone formation
as illustrated by unmeasurable osteoid volume and
osteoblast surface. His osteoclast surface was normal
and he had no marrow fibrosis. All other subjects had
resorptive lesions with increased osteoclast surfaces.
Marrow fibrosis was observed on the biopsy speci-
mens of two children from group Il-A (patients 6 and
7), and one from group Il-B (patient 10). Osteoblast
surface was slightly increased in patient 6, at the
lower limits of normal, or clearly below normal in the
others.
a. Patients treated with 25-(OH)D3 plus orally ad-
ministered calcium (Group 11-A). Among the four sub-
jects treated with 25-(OH)D3 and calcium, orally, two
(patients 6 and 7) were maintained on therapy for 16
and 8 months, respectively, before the second biopsy
was performed. For patients 8 and 9, treatment was
of shorter duratjon, and was interrupted one or more
times because plasma calcium concentration had in-
creased to 11.0 to 11.5 mg/l00 ml (Table 4). Both
children given long-term 25-(OH)D3 therapy had in-
creased osteoid volume and osteoclast surface, and
marrow fibrosis on their first biopsy specimen. Nor-
mal mineralization, disappearance of marrow fibrosis
and diminution of their osteoclast surface were ob-
served on their second biopsy specimen. For the lat-
ter two patients of group 11-A, despite interruptions
in 25-(OH)D3 therapy, histology also indicated a de-
crease in osteoclast surface in one case (patient 8),
and a normalization of this parameter in the case of
patient 9. The mean osteoid seam thickness decreased
during treatment in all the children of group Il-A.
The relative osteoblastic activity decreased in three
cases (patients 6, 8 and 9) and did not change in one
case (patient 7). It should be noted that the child
(patient 8), whose plasma calcium concentration rose
to 11.5 mg/100 ml after 50tg/day of 25-(OH)D3 for
three weeks, had undergone bilateral nephrectomy at
the initiation of this treatment (Table 4). For the
children of group It-A, plasma calcium concentra-
tions varied from 8.5 to 11.5 mg/l00 ml and plasma
phosphorus from 2.1 to 11.0 mg/l00 ml (Fig. 4, a and
b). Plasma alkaline phosphatase concentrations re-
mained within the normal range. X-ray examination
showed the disappearance of the discrete lesions of
grade + or (+) for patients 6 and 7, and no detectable
modifications for patients 8 and 9.
b. Patients treated with calcium, orally, alone (group
11-B). Among the children given calcium supplements
orally without additional 25-(OH)D3 therapy (group
Il-B), the follow-up was of three months' duration
for patient 14 who underwent kidney transplantation.
During this short period of time, this patient devel-
oped increased osteoclast surface. For the other
subjects the second biopsy was performed eight
months to one year after the beginning of IHD and
calcium supplementation orally. Histology did not
show the appearance of severe osteodystrophy.
However, osteoid volume and mean osteoid seam
thickness increased in patients 11 and 12. The ag-
gravation observed for patient 11 might have been
related to the fact that this child was dialyzed with
a relatively low calcium fluid, i.e., 3.0 mEq/liter, but
this was not the case for patient 12 who was dialyzed
for 12 months with a fluid containing 3.5 mEq/liter
of calcium. Osteoid volume and mean osteoid seam
thickness decreased in patients 10 and 13 but,
nevertheless, remained abnormally high. The relative
osteoblastic activity increased in four out of five
children (patients 10, 12, 13 and 14). Osteoblast
surface increased slightly in two cases (patients 12
and 13), remained very low in patient 11, and was
E0
E 16
14
12
'to- 100E 826
C,)
D2 I
— Calcitonin
MRCU 300mg/day
diet 100 mg/day
Fig. 3. Changes in serum calcium concentrations of patient 2 intoxicated with 25-(OH)D3.
Nov.
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Daily dose Duration Dose Duration Bone Calcified
/2g/kg months g/day months volume volume
6 Before 25—(O1-1)D3 + Ca
After 25—(OH)D3 + Ca 50 1.5 16
7 Before25—(OH)D3 + Ca
After 25—(OH)D3 + Ca 50 1.1 8
S Before 25—(OH)D3 + Ca 18.5
After 25—(OH)D3 + Ca 150 2.5 21 days
-
0 1½
150 2.5 2½
9 Before 25—(OH)D3 + Ca 20.3
After 25—(OH)D3 + Ca 25
13 Before Ca
After Ca
14 BeforeCa
After Ca
30.0
9 21.6
19.5
3 18.9
23.2
19.3
19.5
18.6
Normal controls N = 13
(mean I SD)
Osteobl. = osteoblast; S = surface; mo = month.
22.0 21.1
+1.87
greatly augmented in patient 10. This latter child had
marrow fibrosis at the time this investigation was
initiated: her fibrosis increased. No lesions of marrow
fibrosis appeared in the other subjects. Osteoclast
surface had further increased in patient 10; decreased,
although remaining very high in patients 11 and 13;
and was not modified in patient 12.
In patients of group lI-B, plasma calcium concen-
trations were variable from a minimal value of 8.3 to
a maximal value of 11.1 mg/lOO ml and plasma phos-
phorus concentrations ranged from 2.6 to 8,2 mg/l00
ml (Fig. 5, a and b). The plasma alkaline phosphatase
concentrations remained elevated throughout the
study in patient 10. For the other subjects the alkaline
phosphatases increased slightly (patients 12 and 13)
or were unchanged (patients 11 and 14). Radiographic
examination of group Il-B children did not show
noticeable modifications during this study except in
one individual (patient 10) in whom the bone resorp-
tion increased.
Discussion
The present data show that at pharmacologic
doses, i.e., 25 to 200tg/day, 25-(OH)D3 is a potent
drug for the treatment of osteodystrophy in children
with terminal renal failure. The morphometric results
clearly indicate that 25-(OH)D3 treatment acts on
matrix formation, mineralization and resorption. The
five children studied initially had severe bone lesions
at the time 25-(OH)D3 therapy was initiated. Plasma
Patient No.
-
Therapy
Table 4. Quantitative histology of patients with near normal radiograms, started on a program of
25—(OH)D3 Calcium, orally
0.75
1.50
16
8
24.6
21.6
25.5
17.4
0.50
0
0.25
21 days
1½
22.2
21.1
20.6
17
17.7
16.4
18.84
10
50
1050
17.0
0.375
2
2
4
1½
3
3
0.50 7½ 18.2 17.1
10 Before Ca
After Ca 0.75 8
33.6
20.3
20.6
16.4
Ii Before Ca
After Ca 0.50 8
15.5
20.8
14.8
17.4
12 BeforeCa
AfterCa 0.75 12
28.0
31.6
25.9
26.3
0.75
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intermittent hemodialysis and given 25—(OH)D3 plus calcium, orally, or calcium, orally, alonea
Bone histology Remarks
Osteoid
volume
Osteoid
surface
thickness
(pm)
Osteoblast
surface
Osteobi S
Osteoid S
%
Marrow
fibrosis
Osteoclast
surface
2.4
0.5
4.9
0.4
23.5
17.1
54.0
18.3
26.7
10.5
9.2
3.8
13.4
3.1
5.0
2.0
57
18.1
9.3
10.9
4.8
0
2.6
0
18.9
8.2
5.4
3.2
Binephrectomy 2 mo before the second
bone biopsy
0.8 16.5 6.1 5.8 35.1 0 8.2 Binephrectomy just before 25—(OH)D
therapy, plasma calcium (11.5 mg/l00 ml)
0.6 21.0 5.8 4.3 20.5 0 5.6
1.5 32.6 9.1 6.3 19.3 0 5.1
Plasma calcium (11.0 mg/l00 ml)
1.1 27.2 4.8 4.5 16.5 0 1.9
12.6
3.8
82.6
56.9
36.4
13.4
2.2
19.2
2.7
33.9
2.3
4.3
5.9
7.8
0.7
3.4
2.!
5.3
9.4
15.7
16.7
37.6
17.4
41
6.3
34.6
3.9
0
1.6
6.3
41.5
—
9.6
16.8
0
0
0
0
11.2
6.7
7.8
7.4
Binephrectomy 5 mo before the second
biopsy
6.8
2.3
39.3
11.6
28.8
25.2
2.6
6.6
6.6
56.9
0
0
7.9
3.1
0
0.2
0.6
5.9 19.3
0
2.8
—
47.5
0
0
2.2
4 Anephric
0.9 22.0 9.3 8.3 36.9 0 1.8
alkaline phosphatase activities were elevated in all.
No relationship was established between plasma cal-
cium, plasma phosphorus concentrations and the
type or severity of the histologic abnormalities seen
on biopsy. The lack of reliability of these latter bio-
chemical parameters for the prediction of histologic
or X-ray lesions in patients with chronic renal
failure is in agreement with our past experience [1]
and with the observations of others [18-241. Among
the five patients, the severity and distribution of bone
lesions, i.e., osteoid volume and osteoid surface, aug-
mentation of osteoblast and osteoclast surfaces, pres-
ence of marrow fibrosis and of osteolytic lacunae,
were similar in the subjects who had never received
supplementary vitamin D and in those previously
treated with vitamin D. These results, and the fact
that for one subject (Table 3, patient 5) five months
of vitamin D therapy between the first and the second
biopsy did not improve bone abnormalities, suggest
that vitamin D, at the doses utilized in this study (345
to 685zg/day or 13,000 to 28,400 lU/day), is unable
to promote healing of severe skeletal lesions in termi-
nal renal failure.
In the group of children with essentially normal
radiograms at the institution of intermittent hemo-
dialysis, the first iliac crest biopsy specimen showed
lesions of resorption in eight patients out of nine, a
finding in agreement with the observations of other
investigators [25—281.
Four subjects were given calcium supplements
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orally (0.25 to 1 .5 g/day) plus 25 to 50/Lg/day of 25-
(OH)D3. An improvement of the histologic lesions
was observed for these patients, although none of
them had a completely normal bone at the end of the
study. For five patients given calcium, orally, alone,
results were less satisfactory. Mean seam thickness,
indicating the balance between matrix formation and
mineralization, was found normalized in one subject
(Table 4, patient 10); a defect in the process of miner-
alization appeared (patients 12 and 14), remained
unchanged (patient 13) or was aggravated (patient
11) in the others. Marrow fibrosis, when present, had
increased (patient 10).
These two groups of patients were comparable at
the beginning and during the study in many respects:
age groups, proportion of congenital disease with a
long duration versus acquired disease with a shorter
of calcium, thick arrows indicate dialysate containing 7 mg/l00 ml
of calcium. For each subject the two stars indicate the first and the
second bone biopsy. Dashed area shows the upper and lower
normal values for serum calcium; dotted lines indicate 6 mg/l00 ml
of serum phosphorus concentration; this is the limit of acceptable
hyperphosphatemia.
duration, number of anephric patients (Table 4), var-
iations of individual plasma calcium and phosphorus
concentrations (Fig. 4 and 5), roentgenographic find-
ings. But, they were not identical. The oldest subject
(patient 7), an adolescent aged 15 yr, in group Il-A,
treated with 25-(OH)D3 and calcium supplement,
was given a larger dose of calcium than the other
subjects. One subject in each group (patients 6
and II) was started on IHD with a dialysate of low
calcium concentration (3mEq/liter). After ten
months of IHD, patient 6 was shifted to dialysis with
a 3.5 mEg/liter calcium dialysate, whereas patient 10
was dialyzed throughout the investigation against the
lower calcium bath. Due to the small number of
subjects in each group and to these differences in the
manner in which they were treated, it is difficult to
ascertain that the better therapeutic results achieved
Subject 25-(OH)D
No. 6 pg/d
1:504*0
500
[500
Subject
No. 7
Subject
No. 8
E
E
00
E
C1
0
108
6
*4*i:
_______
1>6
E
Co
10
8
6
2468 10 1214161820
a Months
Fig. 4. Plasma calcium (a) and phosphorus (b) concentrations of
patients of group 11-A. Each point corresponds to the mean value
obtained on eight to ten plasma concentrations measurements per
month; vertical bars represent + I scM; Arrows indicate the begin-
ning of IHD: thin arrows indicate dialysate containing 6 mg/lOO ml
Subject
No. 6 25-(OH)D3
pg/day
1:50
9 1 * 4
______________ Subject [50g *4 * No.7
7
5
3
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7
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* No.9
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b Months
11
10
9
8
7
6
11
10
9
8
7
6
11
10
9
8
7
6
11
10
9
8
7
6
11
10
9
8
7
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9
8
7
6
5
4
3
* Subject
No. 12
Fig. 5. Plasma calcium (a) and phosphorus (b) concentrations of patients of group 11-B. Symbols are the same as for Fig. 4.
with 25-(OH)D3 may be attributable solely to this
vitamin D metabolite.
Finally, concerning the tolerance to long-term
therapy with 25-(OH)D3, the present data show two
points: 1) the tolerance to pharmacologic doses of 25-
(OH)D3 is variable among children with terminal
renal failure; 2) such doses may lead to episodes of
hypercalcemia even in anephric patients. In our in-
vestigation, we were unable to relate the degree of
sensitivity to the hypercalcemic action of 25-(OH)D3
to factors such as daily doses of the drug (expressed
in sg or zg/kg of body wt); total dose; the presence
or absence of a previous vitamin D therapy; plasma
calcium, phosphorus, alkaline phosphatase concen-
trations; the type and severity of X-ray and histologic
bone lesions at the time therapy was started. As for
the second point, the episodes of mild or severe hy-
percalcemia that occurred in some patients demon-
strate that when pharmacologic doses are used, 25-
(OH)D3, like vitamin D [29], does not require the
presence of the kidney to induce intoxication.
Recent studies [301 have shown that after direct
administration of 25-(OH)D3 its serum concentration
is directly correlated to doses and that its half-life is
short, whereas after the administration of pharma-
cologic amounts of vitamin D, serum level of endog-
enous 25-(OH)D3 is variable, unpredictable and its
decay is prolonged. These data confirm our clinical
impression and that of other investigators that in
kidney diseases, as in many other pathologic states of
*
*
—
* Subject
No. 10
Subject
No. 11
Subject
No. 10
Subject
No. 11
Subject
No. 12
Subject
No. 13
E
I
*
4 *
— 11-
E 10-
9.
E
E 5
4.
3.9 *8
b
* *
Subject
________
No. 14
Subject
No. 13
Subject
No. 14
2 4 6 8 10 12 14
Months
2 4 6 8 10 12 14
Months
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man, therapeutic results are more easily achieved
with 25-(OH)D3 than with vitamin D [11, 31—33].
However, such treatment with 25-(OH)D3 necessi-
tates careful and repeated medical surveillance. Mon-
itoring of serum 25-(OH)D3 concentrations during
therapy should prevent intoxications.
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